Bristol Stuck In Waiting Game As Opdivo TMB Gamble Fails To Pay Off

Withdrawal of filing of CheckMate 227 data in patients with high tumor mutational burden (TMB) means another delay for Opdivo in first-line lung cancer.

high contrast image of casino roulette in motion - Image

Bristol-Myers Squibb Co.'s withdrawal of a high-profile US FDA filing for use of its PD-1 inhibitor Opdivo with its CTLA-4 inhibitor Yervoy in first-line non-small cell lung cancer based on the tumor mutational burden biomarker in the CheckMate 227 study puts more pressure on pipeline assets from the newly acquired Celgene Corp. to pay off.

Bristol said on Jan. 24, as part of its fourth-quarter/year-end 2018 earnings report, that it has voluntarily withdrawn the filing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer